within the speedily evolving area of oncology exploration, accurate and efficient mutation screening is critical for acquiring specific therapies. The KRAS companies Platform plays a pivotal part In this particular landscape by supplying complete remedies for KRAS mutation profiling and analysis. KRAS mutations, located in roughly 95% of RAS-simila